VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of steady-state telaprevir (TVR) 750
mg q8h (3 times a day, every 8 hours) on the steady-state pharmacokinetics of escitalopram 10
mg q.d. (once a day), and vice versa. Steady state is a term which means that the drug has
been given long enough so that the plasma concentrations will remain the same with each
subsequent dose. TVR is being investigated for the treatment of chronic hepatitis C virus
(HCV) infection. Pharmacokinetics (pk) means how the drug is absorbed into the bloodstream,
distributed in the body and eliminated from the body.